Google Android sales decline 11% in US: Report

https://encrypted-tbn3.gstatic.com/images?q=tbn:ANd9GcRSK3WjtN3-ywqUlDxCTCWbIBfE9EHD47BC0IcsCWrbe3k7g5A21wNew York, Jan 7, 2013: Apple iOS remains the top selling smartphone platform in the US, with 53.3% of the market for the 12-week period ending November 25, 2012, says a report released by Kantar Worldpanel ComTech. This is the first time Apple’s mobile platform has crossed 50% sales share.

According to the report, Android sales share declined by 10.9% to 41.9% in the same period. Windows Phone positioned itself at third place with 2.7% of smartphones sold between August 25 and November 25, 2012 in the US.

Regarding the mobile carriers, AT&T saw success due the iPhone 5 and was the top selling smartphone carrier with 35.4% of smartphones sold in this 12-week period. Verizon was second with 31.9% of smartphones sold. And Sprint was third, with 14.5% of sales, sees the largest decrease year-on-year, down 5%.

According to Kantar Worldpanel ComTech, the data comes from its USA consumer panel, which it claims is the largest continuous consumer research mobile phone panel of its kind in the world. Their analyst Mary-Ann Parlato says, “The iPhone 5 has been successful this period; however, we also see that Apple’s older models – iPhone 4S and 4 have also contributed to the growing share of iOS. This is particularly the case for first-time smartphone iPhone buyers where we see the older models still selling well amongst this group.”

Pfizer To Market Biocon’s Insulin Products Globally

October 19, 2010 by · Leave a Comment
Filed under: Americas, Biotech, Europe, Healthcare, JVs, Marketing, Pharma 

http://www.wcgt.in/html/assets/biocon-logo.jpgOctober 19, 2010, Bangalore, India: Bangalore-based biotech company Biocon has entered into an agreement with Pfizer, the world’s biggest pharma company, under which the latter will pay $200 million (about Rs 900 crore) to have exclusive rights to commercialize several of Biocon’s insulin products globally.

Under the agreement, Biocon is also eligible to receive from Pfizer an additional payment of $150 million towards further development of the drugs and to meet regulatory milestones. It would also receive payment linked to Pfizer’s sales of the insulin products.

The two companies came together on Monday to announce the agreement and said that Pfizer would have the rights to commercialize Biocon’s biosimilar versions of insulin and what are called insulin analog products – Recombinant Human Insulin, Glargine, Aspart and Lispro. An insulin analog is an altered form of insulin, different from any occurring in nature, but still available to the human body for performing the same action as human insulin in terms of glycemic control. Read more

Next Page »